The latest price target for Molecular Templates (NASDAQ:MTEM) was reported by Barclays on November 11, 2022. The analyst firm set a price target for $1.00 expecting MTEM to rise to within 12 months (a possible 587.29% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Molecular Templates (NASDAQ:MTEM) was provided by Barclays, and Molecular Templates maintained their overweight rating.

There is no last upgrade for Molecular Templates

The last downgrade for Molecular Templates Inc happened on May 27, 2022 when B of A Securities changed their price target from N/A to $1.5 for Molecular Templates Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Templates, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Templates was filed on November 11, 2022 so you should expect the next rating to be made available sometime around November 11, 2023.

While ratings are subjective and will change, the latest Molecular Templates (MTEM) rating was a maintained with a price target of $4.50 to $1.00. The current price Molecular Templates (MTEM) is trading at is $0.15, which is out of the analyst’s predicted range.